Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Colonic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 11Oxaliplatin 9Fluorouracil 9Leucovorin 7Irinotecan 7Gemcitabine 7Nivolumab 6Biopsy 6Bevacizumab 6pembrolizumab 5lenvatinib 5Specimen Handling 5Radiosurgery 5Cisplatin 5Capecitabine 5X-Rays 4Radiation 4Proflavine 4Oncolytic Virotherapy 4Cyclophosphamide 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4sodium thiosulfate 3gallium 68 PSMA-11 3folfirinox 3Surgical Procedures, Operative 3Paclitaxel 3Omeprazole 3Ketamine 3Immune Checkpoint Inhibitors 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × epigallocatechin gallate × Gastrointestinal × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡